vs
KFORCE INC（KFRC）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
KFORCE INC的季度营收约是REPLIGEN CORP的1.7倍（$330.4M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs 2.4%，领先4.3%），REPLIGEN CORP同比增速更快（13.6% vs 0.1%），REPLIGEN CORP自由现金流更多（$17.6M vs $-7.4M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs -3.7%）
Kforce Inc.是一家总部位于美国的专业人力资源服务与解决方案供应商，业务覆盖技术、财务会计、医疗保健三大核心领域，为全美各类中大型企业提供专业人才派遣、劳动力管理优化等定制服务。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
KFRC vs RGEN — 直观对比
营收规模更大
KFRC
是对方的1.7倍
$197.9M
营收增速更快
RGEN
高出13.5%
0.1%
净利率更高
RGEN
高出4.3%
2.4%
自由现金流更多
RGEN
多$25.0M
$-7.4M
两年增速更快
RGEN
近两年复合增速
-3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $330.4M | $197.9M |
| 净利润 | $7.9M | $13.3M |
| 毛利率 | 27.3% | 52.5% |
| 营业利润率 | 3.6% | 9.0% |
| 净利率 | 2.4% | 6.7% |
| 营收同比 | 0.1% | 13.6% |
| 净利润同比 | -2.7% | 143.9% |
| 每股收益（稀释后） | $0.46 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KFRCRGEN
| Q1 26 | $330.4M | — | ||
| Q4 25 | $332.0M | $197.9M | ||
| Q3 25 | $332.6M | $188.8M | ||
| Q2 25 | $334.3M | $182.4M | ||
| Q1 25 | $330.0M | $169.2M | ||
| Q4 24 | $343.8M | $174.1M | ||
| Q3 24 | $353.3M | $154.9M | ||
| Q2 24 | $356.3M | $154.1M |
净利润KFRCRGEN
| Q1 26 | $7.9M | — | ||
| Q4 25 | $5.2M | $13.3M | ||
| Q3 25 | $11.1M | $14.9M | ||
| Q2 25 | $10.4M | $14.9M | ||
| Q1 25 | $8.1M | $5.8M | ||
| Q4 24 | $11.1M | $-30.3M | ||
| Q3 24 | $14.2M | $-654.0K | ||
| Q2 24 | $14.2M | $3.3M |
毛利率KFRCRGEN
| Q1 26 | 27.3% | — | ||
| Q4 25 | 27.2% | 52.5% | ||
| Q3 25 | 27.7% | 53.2% | ||
| Q2 25 | 27.1% | 50.0% | ||
| Q1 25 | 26.7% | 53.6% | ||
| Q4 24 | 27.0% | 26.1% | ||
| Q3 24 | 27.9% | 50.0% | ||
| Q2 24 | 27.8% | 49.8% |
营业利润率KFRCRGEN
| Q1 26 | 3.6% | — | ||
| Q4 25 | 2.6% | 9.0% | ||
| Q3 25 | 4.5% | 8.9% | ||
| Q2 25 | 4.5% | 7.6% | ||
| Q1 25 | 3.5% | 3.9% | ||
| Q4 24 | 4.5% | -17.7% | ||
| Q3 24 | 5.3% | -5.1% | ||
| Q2 24 | 5.5% | 1.0% |
净利率KFRCRGEN
| Q1 26 | 2.4% | — | ||
| Q4 25 | 1.6% | 6.7% | ||
| Q3 25 | 3.3% | 7.9% | ||
| Q2 25 | 3.1% | 8.2% | ||
| Q1 25 | 2.5% | 3.4% | ||
| Q4 24 | 3.2% | -17.4% | ||
| Q3 24 | 4.0% | -0.4% | ||
| Q2 24 | 4.0% | 2.2% |
每股收益（稀释后）KFRCRGEN
| Q1 26 | $0.46 | — | ||
| Q4 25 | $0.29 | $0.24 | ||
| Q3 25 | $0.63 | $0.26 | ||
| Q2 25 | $0.59 | $0.26 | ||
| Q1 25 | $0.45 | $0.10 | ||
| Q4 24 | $0.60 | $-0.55 | ||
| Q3 24 | $0.75 | $-0.01 | ||
| Q2 24 | $0.75 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3M | $767.6M |
| 总债务越低越好 | — | $542.2M |
| 股东权益账面价值 | $117.4M | $2.1B |
| 总资产 | $384.8M | $2.9B |
| 负债/权益比越低杠杆越低 | — | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资KFRCRGEN
| Q1 26 | $1.3M | — | ||
| Q4 25 | $2.1M | $767.6M | ||
| Q3 25 | $1.3M | $748.7M | ||
| Q2 25 | $2.5M | $708.9M | ||
| Q1 25 | $444.0K | $697.2M | ||
| Q4 24 | $349.0K | $757.4M | ||
| Q3 24 | $127.0K | $784.0M | ||
| Q2 24 | $110.0K | $809.1M |
总债务KFRCRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | $542.2M | ||
| Q3 25 | — | $537.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $525.6M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益KFRCRGEN
| Q1 26 | $117.4M | — | ||
| Q4 25 | $124.6M | $2.1B | ||
| Q3 25 | $132.1M | $2.1B | ||
| Q2 25 | $134.4M | $2.1B | ||
| Q1 25 | $138.0M | $2.0B | ||
| Q4 24 | $154.6M | $2.0B | ||
| Q3 24 | $167.4M | $2.0B | ||
| Q2 24 | $166.6M | $2.0B |
总资产KFRCRGEN
| Q1 26 | $384.8M | — | ||
| Q4 25 | $365.6M | $2.9B | ||
| Q3 25 | $374.2M | $2.9B | ||
| Q2 25 | $373.6M | $2.9B | ||
| Q1 25 | $368.2M | $2.9B | ||
| Q4 24 | $357.8M | $2.8B | ||
| Q3 24 | $369.9M | $2.8B | ||
| Q2 24 | $362.7M | $2.9B |
负债/权益比KFRCRGEN
| Q1 26 | — | — | ||
| Q4 25 | — | 0.26× | ||
| Q3 25 | — | 0.26× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.27× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-7.4M | $17.6M |
| 自由现金流率自由现金流/营收 | -2.2% | 8.9% |
| 资本支出强度资本支出/营收 | 1.0% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $43.3M | $93.9M |
8季度趋势，按日历期对齐
经营现金流KFRCRGEN
| Q1 26 | — | — | ||
| Q4 25 | $19.7M | $25.7M | ||
| Q3 25 | $23.3M | $48.1M | ||
| Q2 25 | $18.4M | $28.6M | ||
| Q1 25 | $249.0K | $15.0M | ||
| Q4 24 | $21.8M | $39.2M | ||
| Q3 24 | $31.0M | $49.3M | ||
| Q2 24 | $20.9M | $42.2M |
自由现金流KFRCRGEN
| Q1 26 | $-7.4M | — | ||
| Q4 25 | $16.7M | $17.6M | ||
| Q3 25 | $19.8M | $43.4M | ||
| Q2 25 | $14.2M | $21.5M | ||
| Q1 25 | $-3.9M | $11.4M | ||
| Q4 24 | $20.9M | $33.6M | ||
| Q3 24 | $27.5M | $42.3M | ||
| Q2 24 | $17.8M | $37.4M |
自由现金流率KFRCRGEN
| Q1 26 | -2.2% | — | ||
| Q4 25 | 5.0% | 8.9% | ||
| Q3 25 | 6.0% | 23.0% | ||
| Q2 25 | 4.3% | 11.8% | ||
| Q1 25 | -1.2% | 6.8% | ||
| Q4 24 | 6.1% | 19.3% | ||
| Q3 24 | 7.8% | 27.3% | ||
| Q2 24 | 5.0% | 24.3% |
资本支出强度KFRCRGEN
| Q1 26 | 1.0% | — | ||
| Q4 25 | 0.9% | 4.1% | ||
| Q3 25 | 1.1% | 2.5% | ||
| Q2 25 | 1.2% | 3.9% | ||
| Q1 25 | 1.3% | 2.1% | ||
| Q4 24 | 0.3% | 3.2% | ||
| Q3 24 | 1.0% | 4.5% | ||
| Q2 24 | 0.9% | 3.1% |
现金转化率KFRCRGEN
| Q1 26 | — | — | ||
| Q4 25 | 3.82× | 1.93× | ||
| Q3 25 | 2.11× | 3.23× | ||
| Q2 25 | 1.76× | 1.92× | ||
| Q1 25 | 0.03× | 2.57× | ||
| Q4 24 | 1.97× | — | ||
| Q3 24 | 2.18× | — | ||
| Q2 24 | 1.48× | 12.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
